The Indian Patent Office has rejected Viiv Healthcare's patent application for the HIV drug, dolutegravir, after nearly a decade of legal battles. This decision opens the market for generic versions, promoting affordable access to treatment and potentially reducing costs. The ruling addresses concerns over 'evergreening' practices in patent filings.
October 16, 2024 at 01:16AM
from Times of India
https://ift.tt/0giV9BD
Patent for HIV drug rejected, paves way for entry of generics
Subscribe to:
Post Comments (Atom)
Patriots WR Mack Hollins steals show going shirtless and barefoot in the cold
Patriots receiver Mack Hollins made a memorable entrance for a snow-filled game, arriving shirtless and barefoot despite freezing temperatur...
-
A potential collision was averted at Delhi's IGIA when an Indian carrier's A320, arriving from Phuket, slowed down and failed to pro...
-
An Amarnath Yatra convoy vehicle met with an accident in Udhampur, injuring the driver, while 7,579 pilgrims embarked from Jammu for the hol...
-
Tea bags offer quick, consistent brews with smaller leaf particles, ideal for busy mornings. Loose-leaf tea, featuring whole leaves, provide...
No comments:
Post a Comment